NYSE:ENOV - New York Stock Exchange, Inc. - US1940141062 - Common Stock - Currency: USD
30.11
-0.55 (-1.79%)
The current stock price of ENOV is 30.11 USD. In the past month the price decreased by -6.92%. In the past year, price decreased by -33.22%.
Symbol | Company Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
ABT | ABBOTT LABORATORIES | 27.82 | 231.38B | ||
ISRG | INTUITIVE SURGICAL INC | 66.67 | 182.56B | ||
BSX | BOSTON SCIENTIFIC CORP | 37.52 | 149.87B | ||
SYK | STRYKER CORP | 29.97 | 143.52B | ||
MDT | MEDTRONIC PLC | 15.7 | 110.73B | ||
BDX | BECTON DICKINSON AND CO | 11.95 | 48.27B | ||
EW | EDWARDS LIFESCIENCES CORP | 28.4 | 43.31B | ||
IDXX | IDEXX LABORATORIES INC | 45.96 | 42.46B | ||
RMD | RESMED INC | 27.94 | 37.20B | ||
GEHC | GE HEALTHCARE TECHNOLOGY | 15.5 | 32.64B | ||
DXCM | DEXCOM INC | 48.48 | 31.37B | ||
STE | STERIS PLC | 25.23 | 23.15B |
Enovis Corp. operates as a medical technology growth company. The company is headquartered in Wilmington, Delaware and currently employs 7,367 full-time employees. The company went IPO on 2008-05-08. The company is focused on developing clinically differentiated solutions by manufacturing and distributing high-quality medical devices with a range of products used for reconstructive surgery, rehabilitation, pain management and physical therapy. The company operates through two segments: Prevention & Recovery and Reconstructive. The Prevention & Recovery segment provides orthopedic and recovery science solutions, including devices, software, and services across the patient care continuum from injury prevention to rehabilitation after surgery, injury, or from degenerative diseases. The Prevention & Recovery products are marketed under several brand names, such as DJO. The Reconstructive segment provides surgical implant solutions, offering a comprehensive suite of reconstructive joint products for the hip, knee, shoulder, elbow, foot, ankle, and finger and surgical productivity tools. The company also operates a Enovis Growth eXcellence business system (EGX).
ENOVIS CORP
2711 Centerville Road, Suite 400
Wilmington DELAWARE US
Employees: 7367
Phone: 13022529160
The current stock price of ENOV is 30.11 USD. The price decreased by -1.79% in the last trading session.
The exchange symbol of ENOVIS CORP is ENOV and it is listed on the New York Stock Exchange, Inc. exchange.
ENOV stock is listed on the New York Stock Exchange, Inc. exchange.
17 analysts have analysed ENOV and the average price target is 59.84 USD. This implies a price increase of 98.74% is expected in the next year compared to the current price of 30.11. Check the ENOVIS CORP stock analysts ratings, price target forecast and up-and down grades for more detailed information.
ENOVIS CORP (ENOV) has a market capitalization of 1.72B USD. This makes ENOV a Small Cap stock.
ENOVIS CORP (ENOV) currently has 7367 employees.
ENOVIS CORP (ENOV) has a resistance level at 31.84. Check the full technical report for a detailed analysis of ENOV support and resistance levels.
The Revenue of ENOVIS CORP (ENOV) is expected to grow by 6.39% in the next year. Check the estimates tab for more information on the ENOV EPS, Sales, EBIT and EBITDA future analyst estimates.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
ENOV does not pay a dividend.
ENOVIS CORP (ENOV) will report earnings on 2025-08-05, before the market open.
The PE ratio for ENOVIS CORP (ENOV) is 9.59. This is based on the reported non-GAAP earnings per share of 3.14 and the current share price of 30.11 USD. Check the full fundamental report for a full analysis of the valuation metrics for ENOV.
The outstanding short interest for ENOVIS CORP (ENOV) is 11.53% of its float. Check the ownership tab for more information on the ENOV short interest.
ChartMill assigns a fundamental rating of 4 / 10 to ENOV. ENOV has a bad profitability rating. Also its financial health evaluation is rather negative.
Over the last trailing twelve months ENOV reported a non-GAAP Earnings per Share(EPS) of 3.14. The EPS increased by 27.64% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | N/A | ||
ROA | -16.6% | ||
ROE | -30.92% | ||
Debt/Equity | 0.52 |
ChartMill assigns a Buy % Consensus number of 84% to ENOV. The Buy consensus is the average rating of analysts ratings from 17 analysts.
For the next year, analysts expect an EPS growth of 9.12% and a revenue growth 6.39% for ENOV